Christophe Borg

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.6K citations

Oncology, Hepatology, α-Fetoprotein Concentrations +10

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Bernard Escudier, Thierry Dorval, Nathalie Chaput et al. · Journal of Translational Medicine · 2005 · 1.2K citations · Full text

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Gastrointestinal Oncology, Medicine, Randomised Phase 3 +7

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells

Fanny Chalmin, Sylvain Ladoire, Grégoire Mignot et al. · Journal of Clinical Investigation · 2010 · 978 citations · Full text

Human Mdscs, Immunology, Extracellular Microvesicles +16